Abstract Details

Title A Retrospective Chart Review of 49 Patients referred for Skin Punch Biopsy for Small Fiber Neuropathy Symptoms

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-029

Objective In this study, we aimed to characterize clinical and skin biopsy findings and identify the patterns in patients referred to us from 2016 to 2018.

Background The gold standard of small fiber neuropathy (SFN) is the quantification of intradermal nerve fiber density (IENFD) in combination with history and physical exam.

Design/Methods

We screened our database and performed chart review. We classified skin biopsy results into 3 groups: Abnormal IENFD at all sites, non-length dependent, and length dependent. We identified patient demographics and potential etiologies of small fiber neuropathy in these three groups.

Results We had a total of 49 patients, ranging from age 19 to 79. 39 were female. For those patients who reported ethnicity: 76% were Caucasian, 9% Hispanic, 9% Asian, and 6% African American. 65% had pathology consistent with SFN. In patients with abnormal pathology, 53% had abnormal IENFD at all sites, 31% had non-length dependent SFN (NLDSFN), and 16% had length dependent SFN (LDSFN). In those with abnormal IENFD at all sites, 83% were female, 53 % Caucasian, 65% had idiopathic etiology, and 29% had impaired glucose metabolism. 18% of patients had fibromyalgia. In the NLDSFN group, 80% were female, 80% were Caucasian, and 60% had idiopathic etiology. 10% of patients had fibromyalgia. In LDSFN group, 80% were female, 60% were Caucasian, and 60% had idiopathic etiology. 40 % of patients had fibromyalgia.

Conclusions Upon data review, we noted a predominance of female patients (53% abnormal IENFD at all sites, 33% NLDSFN, 16% LDSFN). In abnormal IENFD at all sites, etiology was predominantly impaired glucose metabolism compared to the rest that were predominantly idiopathic etiology. Fibromyalgia was diagnosed in 18% of abnormal IENFD at all sites patients and 40% in LDSFN patients.

Authors/Disclosures
Samarjeet Bajwa, MD PRESENTER	No disclosure on file
Leila Darki, MD, FAAN (USC NeuroSciences)	Dr. Darki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Trinity Partner. Dr. Darki has received personal compensation in the range of $0-$499 for serving as a Consultant for Guide point Global. Dr. Darki has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Global Access Meetings. Dr. Darki has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx . Dr. Darki has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx.
Said R. Beydoun, MD, FAAN (University of Southern California Healthcare Consultation Center 2)	Dr. Beydoun has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Beydoun has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alnylam. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for CSL. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Takeda. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Janssen. The institution of Dr. Beydoun has received research support from Abcuro. The institution of Dr. Beydoun has received research support from Sean Healy & AMG Center for ALS. The institution of Dr. Beydoun has received research support from Regeneron. The institution of Dr. Beydoun has received research support from RemeGen. The institution of Dr. Beydoun has received research support from Sanofi. The institution of Dr. Beydoun has received research support from Novartis.

��ɫ��

��ɫ��